Vor Biopharma (VOR) Non Operating Income (2020 - 2026)

Vor Biopharma (VOR) has reported Non Operating Income for 7 consecutive years, with -$184.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non Operating Income fell 23009.94% year-over-year to -$184.4 million; the TTM figure through Mar 2026 stood at -$509.6 million (down 14437.9% YoY), while the FY2025 annual figure was -$324.3 million, down 7693.98% from the prior year.
• Non Operating Income eased to -$184.4 million in Q1 2026 per VOR's latest filing, from $1.8 billion in the prior quarter.
• Across five years, Non Operating Income topped out at $1.8 billion in Q4 2025 and bottomed at -$1.3 billion in Q2 2025.
• Historically, Non Operating Income has averaged -$29.1 million across 5 years, with a median of $815000.0 in 2022.
• On a YoY basis, Non Operating Income climbed as much as 293525.71% in 2025 and fell as far as 108744.23% in 2025.
• Vor Biopharma's Non Operating Income stood at $815000.0 in 2022, then jumped by 128.59% to $1.9 million in 2023, then slumped by 67.85% to $599000.0 in 2024, then jumped by 293525.71% to $1.8 billion in 2025, then sank by 110.49% to -$184.4 million in 2026.
• Business Quant data shows VOR's Non Operating Income at -$184.4 million in Q1 2026, $1.8 billion in Q4 2025, and -$784.6 million in Q3 2025.